The American Journal of Managed Care

MajesTEC-3 and the Future of Combination Regimens in Multiple Myeloma

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...
Healio

Maintenance combination extends PFS in newly diagnosed multiple myeloma

Please provide your email address to receive an email when new articles are posted on . Patients had a reduced risk for disease progression or death when treated with daratumumab-lenalidomide vs.
Healio

Combination induces durable responses in advanced multiple myeloma

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...
Business Insider

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients Paris, December 9, 2024. New data from three oral presentations, which demonstrated ...
Morningstar

Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma

LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with ...
Seeking Alpha

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in ...